YOLFTbeta
Kyntra Bio, Inc.

Kyntra Bio, Inc.

KYNB · NASDAQ · Healthcare / Biotechnology

3.44USD-0.15 (-4.18%)

Price History

Full chart

Market Stats

Previous Close3.59
Open3.63
Day Range3.34 – 3.99
52-Week Range6.32 – 12.46
Volume13.83K
Market Cap28.10M
P/E (TTM)0.00
Forward P/E61.35
EPS-7.64
Dividend Yield0.00%
Beta1.06
50-Day Avg7.41
200-Day Avg7.53

About

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thane Wettig
  • Employees34
  • Headquarters350 Bay Street, San Francisco, CA, United States, 94133, USA
  • Websitehttps://www.kyntrabio.com

Leadership

  • Mr. Thane WettigCEO & Director · b. 1965
  • Mr. David DeLuciaSenior VP & CFO · b. 1989
  • Mr. John AldenCorporate Secretary & General Counsel
  • Ms. Michelle SimonettiHead of People and Culture & Executive Director
  • Dr. Carrie Brownstein M.D.Chief Medical Officer · b. 1970
  • Ms. Gaia Vasiliver-ShamisDirector of IR & Communications - LifeSci Advisors
  • Ms. Carol GaddumVice President of Product Development

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue65.93M102.17M137.60M180.83M179.58M125.67M212.96M256.58M176.32M235.31M140.73M46.80M29.62M6.44M
Growth (%)-+54.96%+34.68%+31.41%-0.69%-30.02%+69.46%+20.48%-31.28%+33.46%-40.19%-66.74%-36.71%-78.26%
Cost of Revenue74.22M85.71M150.79M214.09M187.21M196.52M235.84M1.15M8.87M449.19M20.28M3.96M15.56M556.00K
Gross Profit-8.29M16.46M-13.19M-33.26M-7.63M-70.85M-22.88M255.43M167.45M-213.88M120.45M42.84M14.06M5.88M
Gross Margin-12.57%16.11%-9.59%-18.39%-4.25%-56.38%-10.74%99.55%94.97%-90.89%85.59%91.53%47.47%91.37%
Operating Expense18.93M24.41M36.91M44.36M46.02M51.76M63.81M344.74M359.33M74.65M421.48M365.56M164.48M51.78M
Operating Income-27.22M-7.95M-50.10M-77.63M-53.65M-122.61M-86.69M-89.31M-191.88M-288.53M-301.02M-322.72M-150.42M-45.90M
Operating Margin-41.29%-7.78%-36.41%-42.93%-29.88%-97.57%-40.71%-34.81%-108.83%-122.62%-213.90%-689.53%-507.80%-712.66%
EBITDA-17.05M843.00K-43.93M-68.83M-44.99M-104.75M-68.56M-52.31M-164.28M-333.72M-282.82M-305.20M-142.43M-57.55M
EBITDA Margin-25.86%0.83%-31.92%-38.06%-25.05%-83.35%-32.20%-20.39%-93.17%-141.82%-200.96%-652.09%-480.83%-893.57%
Net Income-32.57M-14.94M-59.50M-85.78M-61.68M-126.20M-86.42M-76.97M-189.29M-290.02M-293.65M-284.23M-47.58M183.45M
Net Income Margin-49.40%-14.63%-43.24%-47.44%-34.35%-100.43%-40.58%-30.00%-107.36%-123.25%-208.66%-607.29%-160.63%2848.63%
R&D74.22M85.71M150.79M214.09M187.21M196.52M235.84M209.26M252.92M387.04M296.79M266.47M95.69M23.52M
R&D as % of Total Revenue112.57%83.89%109.59%118.39%104.25%156.38%110.74%81.56%143.45%164.48%210.89%569.35%323.05%365.17%
Interest Expense10.03M10.70M11.11M11.03M10.72M9.71M10.99M2.88M2.40M1.07M1.44M8.10M8.25M8.76M
Interest Expense % of Total Revenue15.21%10.47%8.07%6.10%5.97%7.72%5.16%1.12%1.36%0.46%1.02%17.30%27.84%136.01%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets265.59M296.95M483.53M470.57M469.55M898.65M880.60M857.40M826.84M773.82M610.09M423.53M214.53M119.59M
Total Liabilities143.40M189.35M242.85M273.75M294.44M316.20M352.13M321.99M385.39M544.71M611.57M585.73M398.16M115.12M
Total Equity94.48M79.73M221.41M177.55M155.84M563.18M509.20M516.13M422.18M209.15M-21.45M-204.17M-225.60M-30.04M
Cash38.87M76.33M165.46M153.32M173.78M673.66M89.26M126.27M678.39M171.22M155.70M113.69M50.48M47.87M
Total Debt93.23M96.81M97.22M97.04M97.35M97.76M97.16M51.89M39.76M99.72M89.89M170.46M73.09M85.54M
Net Debt54.36M20.48M-68.23M-56.28M-76.43M-575.89M7.90M-74.38M-638.63M-71.50M-65.81M56.77M22.61M-47.87M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.61M25.92M22.41M-18.57M7.11M-66.51M-76.14M-78.70M81.60M-82.23M-145.93M-315.02M-138.00M-4.77M
Investing Cash Flow19.15M10.78M-107.29M-5.87M6.62M69.87M-522.12M120.02M452.49M-426.97M89.12M153.66M125.99M35.42M
Financing Cash Flow6.81M680.00K174.09M12.35M6.74M496.47M13.88M-4.30M13.34M-563.00K46.78M122.75M-255.00K-86.03M
Capital Expenditure744.00K6.81M8.12M1.98M1.25M8.50M8.02M5.76M3.99M30.19M38.74M2.52M266.00K38.00K
Free Cash Flow-6.35M19.11M14.30M-20.55M5.86M-75.01M-84.16M-84.47M77.61M-112.42M-184.67M-317.54M-138.26M-4.81M
Dividends Paid------------2.23M3.95M
FCF to OCF113.27%73.74%63.78%110.65%82.39%112.78%110.53%107.32%95.11%136.71%126.55%100.80%100.19%100.80%
Dividend Paid to FCF-------------1.61%-82.02%

Earnings

Report DateDec 3, 2014Mar 27, 2015May 12, 2015Aug 13, 2015Nov 12, 2015Mar 1, 2016May 9, 2016Aug 8, 2016Nov 8, 2016Mar 2, 2017May 9, 2017Aug 7, 2017Nov 8, 2017Feb 28, 2018May 9, 2018Aug 7, 2018Nov 8, 2018Feb 28, 2019May 9, 2019Aug 8, 2019Nov 11, 2019Mar 2, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Feb 27, 2023May 8, 2023Aug 7, 2023Nov 6, 2023Feb 26, 2024May 6, 2024Aug 6, 2024Nov 12, 2024Mar 17, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Mar 17, 2026May 11, 2026Aug 13, 2026Nov 9, 2026
EPS Estimate---15.2418.59-17.83--12.739.57-16.26--13.10-11.38-10.09--12.77-14.78-10.92--16.55-13.79-14.17-0.59-11.99-19.63-20.14-0.23-22.78-15.6112.08-17.50-0.68-21.31-20.62-0.91-18.95-18.00-17.08-0.44-13.25-6.00-9.50-0.170.501.00-4.00-3.88-3.35-3.18-3.66
EPS Actual-8.28-36.25-19.5020.75-18.50-20.72-11.258.75-9.50-13.35-13.00-12.00-12.50-6.73-12.50-7.00-12.505.74-13.2531.50-14.25-1.12-22.25-23.758.75-0.64-19.50-36.2513.50-36.25-0.68-19.50-24.50-0.70-20.25-22.50-12.98-0.57-8.25-4.000.370.181.25-1.8849.61-3.51-3.76-4.68-
Surprise---27.95%11.62%-3.76%-11.63%-8.57%41.57%-0.76%-5.45%-23.89%-2.11%52.64%-14.47%-19.94%328.43%-0.56%-89.83%-85.57%-20.99%143.45%-173.50%14.40%-132.22%11.76%-107.14%0.00%8.49%-18.82%23.08%-6.86%-25.00%24.00%-29.55%37.74%33.33%103.89%205.88%150.00%-288.00%1340.25%9.65%-12.24%-47.17%-
Timing--Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap28.10M
Enterprise Value79.72M
Trailing P/E0.00
Forward P/E61.35
Price / Sales6.09
Price / Book80.40
EPS-7.64
Book Value-7.45
Revenue (TTM)4.62M
Gross Profit (TTM)-22.57M
EBITDA-50.03M
Profit Margin3968.63%
Operating Margin1191.52%
Return on Equity0.00%
Return on Assets-22.50%
Shares Outstanding4.05M
Shares Float3.56M
Beta1.06
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
24.68%
Insiders
2.02%
Retail / Other
73.30%

Top Institutional Holders

  • Armistice Capital, LLC
    400.00K9.88%
  • Vanguard Capital Management, LLC
    156.61K3.87%
  • Acadian Asset Management LLC
    105.58K2.61%
  • BlackRock Inc
    84.33K2.08%
  • Geode Capital Management, LLC
    46.00K1.14%
  • HighTower Advisors, LLC
    39.74K0.98%
  • Two Sigma Investments LLC
    39.51K0.98%
  • UBS Group AG
    27.59K0.68%
  • Renaissance Technologies Corp
    27.48K0.68%
  • Vanguard Fiduciary Trust Co
    23.94K0.59%
  • Birchview Capital, LP
    22.57K0.56%
  • State Street Corp
    20.28K0.50%
  • GSA Capital Partners LLP
    15.70K0.39%
  • Jane Street Group LLC
    12.23K0.30%
  • ADAR1 Capital Management LLC
    10.47K0.26%
  • Group One Trading, LLC
    4.49K0.11%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    114.18K2.82%
  • Fidelity Extended Market Index
    19.02K0.47%
  • Fidelity Total Market Index
    7.00K0.17%
  • Fidelity Series Total Market Index
    5.74K0.14%

Stock Splits

  • Jun 17, 20251:25